DNA Biomed Solns (DNA) - Net Assets

Latest as of June 2025: ILA98.23 Million ILA ≈ $263.34K USD

Based on the latest financial reports, DNA Biomed Solns (DNA) has net assets worth ILA98.23 Million ILA (≈ $263.34K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA100.00 Million ≈ $268.10K USD) and total liabilities (ILA1.77 Million ≈ $4.76K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DNA asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA98.23 Million
% of Total Assets	98.23%
Annual Growth Rate	19.84%
5-Year Change	1176.13%
10-Year Change	N/A
Growth Volatility	501.04

DNA Biomed Solns - Net Assets Trend (2005–2024)

This chart illustrates how DNA Biomed Solns's net assets have evolved over time, based on quarterly financial data. Also explore DNA Biomed Solns total assets for the complete picture of this company's asset base.

Annual Net Assets for DNA Biomed Solns (2005–2024)

The table below shows the annual net assets of DNA Biomed Solns from 2005 to 2024. For live valuation and market cap data, see DNA company net worth.

Year	Net Assets	Change
2024-12-31	ILA101.47 Million ≈ $272.02K	+28.13%
2023-12-31	ILA79.19 Million ≈ $212.30K	-1.15%
2022-12-31	ILA80.11 Million ≈ $214.76K	+47.44%
2021-12-31	ILA54.33 Million ≈ $145.66K	+583.32%
2020-12-31	ILA7.95 Million ≈ $21.32K	-71.79%
2019-12-31	ILA28.18 Million ≈ $75.56K	-56.58%
2018-12-31	ILA64.90 Million ≈ $174.00K	-6.08%
2017-12-31	ILA69.11 Million ≈ $185.27K	+182.85%
2016-12-31	ILA-83.41 Million ≈ $-223.63K	-899.20%
2015-12-31	ILA-8.35 Million ≈ $-22.38K	+0.11%
2014-12-31	ILA-8.36 Million ≈ $-22.40K	-172.73%
2013-12-31	ILA11.49 Million ≈ $30.80K	-0.30%
2012-12-31	ILA11.53 Million ≈ $30.90K	+10.28%
2011-12-31	ILA10.45 Million ≈ $28.02K	+1705.01%
2010-12-31	ILA579.00K ≈ $1.55K	+108.80%
2009-12-31	ILA-6.58 Million ≈ $-17.64K	-119.37%
2008-12-31	ILA-3.00 Million ≈ $-8.04K	-50.48%
2006-12-31	ILA-1.99 Million ≈ $-5.34K	-161.21%
2005-12-31	ILA3.26 Million ≈ $8.73K	--

Equity Component Analysis

This analysis shows how different components contribute to DNA Biomed Solns's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5144100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	ILA152.91 Million	150.70%
Total Equity	ILA101.47 Million	100.00%

DNA Biomed Solns Competitors by Market Cap

The table below lists competitors of DNA Biomed Solns ranked by their market capitalization.

Company	Market Cap
DOREL INDS INC. B F:DO4B	$34.05 Million
Atlas Engineered Products Ltd V:AEP	$34.05 Million
FASOO.COM Co Ltd KQ:150900	$34.06 Million
Gediz Ambalaj Sanayi ve Ticaret AS IS:GEDZA	$34.07 Million
Buyung Poetra Sembada Tbk PT JK:HOKI	$34.02 Million
I Yuan Precision Ind Co Ltd TWO:2235	$34.02 Million
MST GOLF GROUP BERHAD KLSE:5316	$34.01 Million
Synel M.L.L Payway Ltd TA:SNEL	$33.99 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in DNA Biomed Solns's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 79,187,000 to 101,465,000, a change of 22,278,000 (28.1%).
Net income of 22,096,000 contributed positively to equity growth.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	ILA22.10 Million	+21.78%
Other Changes	ILA182.00K	+0.18%
Total Change	ILA-	28.13%

Book Value vs Market Value Analysis

This analysis compares DNA Biomed Solns's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 125.15x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 36.70x to 125.15x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	ILA2.81	ILA103.10	x
2018-12-31	ILA2.64	ILA103.10	x
2019-12-31	ILA0.93	ILA103.10	x
2020-12-31	ILA0.26	ILA103.10	x
2021-12-31	ILA0.54	ILA103.10	x
2022-12-31	ILA0.65	ILA103.10	x
2023-12-31	ILA0.64	ILA103.10	x
2024-12-31	ILA0.82	ILA103.10	x

Capital Efficiency Dashboard

This dashboard shows how efficiently DNA Biomed Solns utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 21.78%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7220.92%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.03x
Recent ROE (21.78%) is above the historical average (-15.11%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	-18.27%	0.00%	0.00x	2.06x	ILA-2.83 Million
2014	0.00%	0.00%	0.00x	0.00x	ILA-65.57 Million
2015	0.00%	0.00%	0.00x	0.00x	ILA-9.60 Million
2016	0.00%	0.00%	0.00x	0.00x	ILA2.39 Million
2017	213.23%	0.00%	0.00x	1.13x	ILA140.45 Million
2018	-22.01%	0.00%	0.00x	1.24x	ILA-20.78 Million
2019	-136.72%	0.00%	0.00x	1.30x	ILA-41.35 Million
2020	-242.30%	0.00%	0.00x	2.33x	ILA-20.06 Million
2021	33.82%	0.00%	0.00x	1.01x	ILA12.94 Million
2022	-29.38%	-4202.86%	0.01x	1.02x	ILA-31.55 Million
2023	-1.49%	-384.64%	0.00x	1.02x	ILA-9.10 Million
2024	21.78%	7220.92%	0.00x	1.03x	ILA11.95 Million

Industry Comparison

This section compares DNA Biomed Solns's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $114,730,872
Average return on equity (ROE) among peers: -124.90%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
DNA Biomed Solns (DNA)	ILA98.23 Million	-18.27%	0.02x	$34.04 Million
BioLine RX Ltd (BLRX)	$31.77 Million	-32.03%	0.14x	$9.10 Million
BioLight Life Sciences Ltd (BOLT)	$13.31 Million	0.00%	0.69x	$7.66 Million
Bonus Biogroup (BONS)	$84.43 Million	-106.69%	0.24x	$123.99 Million
Can Fite Biopharma Ltd (CANF)	$2.44 Million	-516.99%	2.35x	$5.56 Million
Clal Biotechnology Industries Ltd (CBI)	$808.20 Million	-3.45%	0.28x	$12.61 Million
Compugen (CGEN)	$19.58 Million	-61.30%	0.49x	$201.26 Million
Enlivex Therapeutics Ltd (ENLV)	$8.70 Million	-184.18%	0.22x	$458.60K
Evogene (EVGN)	$56.88 Million	-46.07%	0.26x	$4.88 Million
Kadimastem Ltd (KDST)	$7.28 Million	-173.39%	0.71x	$22.18 Million

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$34.04 Million

ILA12.70 Billion ILA

Market Cap Rank

#23386 Global

#332 in Israel

Share Price

ILA103.10

Change (1 day)

-3.64%

52-Week Range

ILA86.50 - ILA147.50

All Time High

ILA1900.80